Skip to content

US · PTGX · BIOTECHNOLOGY

Protagonist Therapeutics, Inc. (PTGX) intrinsic value and stock valuation

$121.40as of 2026-11-21 · Mkt cap 9.38B

Data updated · price as of 2026-11-21

OvervaluedIC value is 20–50% below the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Protagonist Therapeutics, Inc. DCF and intrinsic value

InvestorsCraft values PTGX with the Chepakovich two-stage DCF model — currently rated overvalued. How the model works · Run your own DCF prefilled from PTGX’s statements →

Protagonist Therapeutics, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Newark, CA 94560 protagonist-inc.com

How the business is doing

Fiscal 2014–2025, USD

Revenue
$46M+10% 5y CAGRd
20142025
Net income
-$-130.15M
20142025
Free cash flow
$56.1M
20142025
Total equity
$614.7M+17.1% 5y CAGRd
20142025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2014–2025, USD
20252024202320222021
Revenue$46M$434.4M$60M$26.6M$27.4M
Operating income-$-158.13M$252.8M-$-93.65M-$-131.37M-$-125.84M
Net income-$-130.15M$275.2M-$-78.95M-$-127.39M-$-125.55M
EPSd-$-2.05M$4.23M-$-1.39M-$-2.6M-$-2.71M
Operating cash flow$57.7M$184.2M-$-70.24M-$-108.14M-$-107.86M
Capital expenditure-$-1.59M-$-1.35M-$-610K-$-800K-$-1.1M
Free cash flow$56.1M$182.8M-$-70.84M-$-108.93M-$-108.97M
Total assets$669.9M$744.7M$358M$247.9M$347.7M
Total debt$10.3M$10.9M$1.14M$3.66M$5.86M
Net debt-$-118.07M-$-86.38M-$-185.59M-$-122.09M-$-117.81M
Total equity$614.7M$675.3M$336.7M$215.6M$300M
Cash and short-term investments$567.4M$418.9M$341.6M$237.4M$326.9M
Income statement
20252024202320222021
Revenue$46M$434.4M$60M$26.6M$27.4M
Cost of revenue$1.23M$0.00$0.00$0.00$0.00
Gross profit$44.8M$434.4M$60M$26.6M$27.4M
Research and development expenses$159.3M$138.1M$120.2M$126.2M$126M
Selling, general and administrative expenses$44.9M$43.5M$33.5M$31.7M$27.2M
Other expenses-$-1.23M$0.00$0.00$0.00$0.00
Operating expenses$202.9M$181.6M$153.7M$158M$153.2M
Cost and expenses$204.1M$181.6M$153.7M$158M$153.2M
Interest income$28.8M$26.3M$14.9M$4.06M$440K
Interest expense$0.00$0.00$0.00$0.00$0.00
Depreciation and amortization$1.23M$830K$3.31M$3.37M$2.77M
Ebitda-$-128.09M$280.2M-$-75.64M-$-124.02M-$-122.78M
Operating income-$-158.13M$252.8M-$-93.65M-$-131.37M-$-125.84M
Total other income/expenses, net$28.8M$26.6M$14.7M$3.98M$290K
Income before tax-$-129.31M$279.4M-$-78.95M-$-127.39M-$-125.55M
Income tax expense$840K$4.22M$0.00$0.00$0.00
Net income-$-130.15M$275.2M-$-78.95M-$-127.39M-$-125.55M
Weighted average shares outstanding$63.6M$61.6M$56.8M$49M$46.3M
Weighted average diluted shares outstanding$63.6M$65.1M$56.8M$49M$46.3M
Balance sheet
20252024202320222021
Cash and short-term investments$567.4M$418.9M$341.6M$237.4M$326.9M
Net receivables$4.5M$168.5M$10.3M$50K$5.33M
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$577.6M$591.6M$355.6M$243.1M$340.7M
Property, plant and equipment, net$11.7M$12.6M$2.15M$4.63M$6.73M
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$78.9M$140.3M$0.00$0.00$0.00
Total non-current assets$92.3M$153.1M$2.37M$4.85M$6.96M
Total assets$669.9M$744.7M$358M$247.9M$347.7M
Accounts payable$5.34M$1.61M$770K$3.64M$1.6M
Short-term debt$2.28M$510K$1.14M$2.52M$2.2M
Deferred revenue$9.55M$18.9M$0.00$70K$2.5M
Total current liabilities$45.4M$47.4M$21.3M$31.2M$44M
Long-term debt$8.04M$10.4M$0.00$1.14M$3.66M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$9.74M$22M$0.00$1.14M$3.66M
Capital lease obligations$8.04M$10.4M$1.14M$3.66M$5.86M
Total liabilities$55.2M$69.4M$21.3M$32.3M$47.7M
Common stock$0.00$0.00$0.00$0.00$0.00
Retained earnings-$-470.67M-$-340.52M-$-615.71M-$-536.75M-$-409.36M
Accumulated other comprehensive income (loss)$640K-$-80K-$-100K-$-360K-$-300K
Total equity$614.7M$675.3M$336.7M$215.6M$300M
Total investments$517.9M$461.9M$154.9M$111.6M$203.2M
Total debt$10.3M$10.9M$1.14M$3.66M$5.86M
Net debt-$-118.07M-$-86.38M-$-185.59M-$-122.09M-$-117.81M
Cash flow statement
20252024202320222021
Net income-$-130.15M$275.2M-$-78.95M-$-127.39M-$-125.55M
Depreciation and amortization$1.28M$2.9M$3.31M$3.37M$2.77M
Stock-based compensation$46M$37.6M$29.3M$24.2M$16.4M
Change in working capital$146.2M-$-122.61M-$-19.51M-$-7.77M-$-3.31M
Accounts receivable$164.9M-$-155M-$-9.99M$4.24M-$-920K
Inventory$0.00$0.00$0.00-$-4.24M$920K
Accounts payable$3.72M$840K-$-2.87M$2.04M-$-1.39M
Net cash provided by operating activities$57.7M$184.2M-$-70.24M-$-108.14M-$-107.86M
Investments in property, plant and equipment-$-1.59M-$-1.35M-$-610K-$-800K-$-1.1M
Acquisitions, net$0.00$0.00$0.00-$-91.47M$14.8M
Net cash used for investing activities-$-49.33M-$-299.48M-$-39.26M$91.5M-$-15.86M
Common stock issued$23.3M$26.5M$132.1M$14.6M$123.8M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$22.9M$25.9M$170.5M$18.8M$129.9M
Net change in cash$31.1M-$-89.48M$61M$2.08M$6.07M
Cash at end of period$128.4M$97.5M$187M$126M$123.9M
Operating cash flow$57.7M$184.2M-$-70.24M-$-108.14M-$-107.86M
Capital expenditure-$-1.59M-$-1.35M-$-610K-$-800K-$-1.1M
Free cash flow$56.1M$182.8M-$-70.84M-$-108.93M-$-108.97M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Protagonist Therapeutics, Inc.

        Protagonist Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering and advancing peptide-based therapies. Their research primarily focuses on treatments for hematological and blood conditions, as well as inflammatory and immune-mediated disorders. The company's pipeline features rusfertide (PTG-300), an injectable hepcidin mimetic currently undergoing Phase II clinical trials for the management of polycythemia vera, hereditary hemochromatosis, and other blood-related ailments. Also in Phase II development is PN-943, an oral peptide engineered as a specific antagonist of alpha-4-beta-7 integrin, intended for addressing inflammatory bowel disease (IBD). Furthermore, they are progressing PN-235, an orally administered antagonist specifically targeting the interleukin-23 receptor, designed for both IBD and various non-IBD therapeutic applications. Protagonist Therapeutics maintains a licensing and collaborative agreement with Janssen Biotech, Inc. Founded in 2006, the company's headquarters are located in Newark, California.

        CEO
        Dinesh V. Patel
        Employees
        132
        Beta
        1.79

        Explore

        Frequently asked questions

        What is the intrinsic value of Protagonist Therapeutics, Inc. (PTGX)?

        Protagonist Therapeutics, Inc. (PTGX) is currently overvalued based on the InvestorsCraft IC model — IC value is 20–50% below the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is PTGX undervalued?

        PTGX trades at a price of $121.40 (Nov 21, 2026): overvalued — IC value is 20–50% below the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.